Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 350

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma

Chi, Dennis S., McCaughty, Kristina, Diaz, John P., Huh, Jae, Schwabenbauer, Sarah, Hummer, Amanda J., Venkatraman, Ennapadam S., Aghajanian, Carol, Sonoda, Yukio, Abu‐Rustum, Nadeem R., Barakat, Richard R. · 2006 · Cancer

Abstract

BACKGROUND: The benefit of cytoreductive surgery for patients with recurrent epithelial ovarian cancer has not been defined clearly. The objective of this study was to identify prognostic factors for survival in patients who underwent secondary cytoreduction for recurrent, platinum‐sensitive epithelial ovarian cancer and to establish generally applicable guidelines and selection criteria. METHODS: The authors reviewed all patients who underwent secondary cytoreduction for recurrent epithelial ovarian cancer from 1987 to 2001. Potential prognostic factors were evaluated in univariate and multivariate analyses. RESULTS: In total, 157 patients underwent secondary cytoreduction, and 153 of those patients were evaluable. After secondary cytoreduction, the median follow‐up was 36.9 months (range, 0.2‐125.6 months), and the median survival was 41.7 months (95% confidence interval, 36.0‐47.2 months). For patients who had a disease‐free interval prior to recurrence of between 6 months and 12 months, the median survival was 30 months compared with 39 months for patients who had a disease‐free interval between 13 months and 30 months and 51 months for patients who had a disease‐free interval >30 months (P = .005). For patients who had a single site of recurrence, the median survival was 60 months compared with 42 months for patients who had multiple sites of recurrence and 28 months for patients who had carcinomatosis (P <.001). The median survival for patients who had residual disease that measured ≤0.5 cm was 56 months compared with 27 months for patients who had residual disease that measured >0.5 cm (P <.001). On multivariate analysis, disease‐free interval (P = .004), the number of recurrence sites (P = .01), and residual disease (P <.001) were significant prognostic factors. CONCLUSIONS: In the authors' analysis of secondary cytoreduction for recurrent epithelial ovarian cancer, a significant survival benefit was demonstrated for residual disease that measured ≤ 0.5 cm. The disease‐free interval and the number of recurrence sites should be used as selection criteria for offering secondary cytoreduction. Cancer 2006. © 2006 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21845

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 350

Metadata

Authors
Chi, D. S., McCaughty, K., Diaz, J. P., Huh, J., Schwabenbauer, S., Hummer, A. J., Venkatraman, E. S., Aghajanian, C., Sonoda, Y., Abu‐Rustum, N. R., & Barakat, R. R.
Venue
Cancer
Publisher
Wiley
Published
2006-03-29
Volume
106
Issue
9
Pages
1933-1939
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2038328856
Cited by
350
References
14
FWCI
16.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma. https://app.cochat.ai/papers/10.1002/cncr.21845
The paper
Chi, D. S., McCaughty, K., Diaz, J. P., Huh, J., Schwabenbauer, S., Hummer, A. J., Venkatraman, E. S., Aghajanian, C., Sonoda, Y., Abu‐Rustum, N. R., & Barakat, R. R. (2006). Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma. Cancer. https://doi.org/10.1002/cncr.21845

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.